Advertisement

Latest News

Taha Qazi, MD: AGA Guideline’s Impact on Pouchitis, Inflammatory Pouch Disorder Management

21 minutes ago

Qazi discusses the impact of having standardized definitions and treatment approaches for pouchitis and inflammatory conditions of the pouch.

Qazi Corner, Edition 5: Tofacitinib, Fenofibrates, Pouchitis Guidelines and BLUE-C

52 minutes ago

The first quarterly issue of 2024 reviews a promising JAK inhibitor for acute severe ulcerative colitis, fenofibrates in PBC, new recommendations from the AGA, and a next generation multi-target DNA stool test for detecting colorectal cancer.

AGA Clinical Guidelines on the Management of Pouchitis and Inflammatory Pouch Disorders

1 hour ago

Recent recommendations from the AGA may help gastroenterologists manage the rising rate of pouchitis with the aid of clinical evidence.

Taha Qazi, MD: Fenofibrate As First-Line Therapy in Primary Biliary Cholangitis

3 hours ago

Qazi discusses a review of the use of fenofibrate as a first-line therapy in treatment-naive patients with PBC and its implications for biochemical response.

Managing Patients With High-Risk PDR and DME

3 hours ago

Ehsan Rahimy, MD, outlines strategies for managing cases of high-risk PDR and DME, exploring new therapies and synergistic combinations with anti-VEGF and steroids for longer-lasting responses.

Advertisement
Advertisement